Finally to define the functional relationship between Th9/IL-9 and dectin-1-activated DC-induced antitumour effects, OT-II mice with established B16-OVA tumours were treated with OVA peptide-pulsed CurDCs in the presence or absence of anti-IL-9. This evidence concerns the gene IL9 and neoplasm.